Adjuvant treatment recommendations in older women with breast cancer - A survey of oncologists Journal Article
| Authors: | Hurria, A.; Naeim, A.; Elkin, E.; Limaye, S.; Grover, A.; Hudis, C.; Pearce, C.; Robson, M. |
| Article Title: | Adjuvant treatment recommendations in older women with breast cancer - A survey of oncologists |
| Abstract: | Objective: Previous studies demonstrate differing treatment patterns between older and younger patients with breast cancer. To explore the reasons for these disparities we conducted a survey of 28 oncologists specializing in breast cancer. Design and methods: Twenty-eight medical oncologists from Memorial Sloan-Kettering Cancer Center and the University of California Los Angeles who specialize in the treatment of breast cancer were asked to provide adjuvant treatment recommendations in hypothetical scenarios featuring older patients with high-risk breast cancer. For each of these hypothetical patients, the patient's age was varied over four possible values (70, 75, 80, or 85 years of age) and health and functional status varied across three possible states (perfect health, average health, or major health problems). Survey data were compiled and analyzed to determine the impact of theoretical patient age, baseline health, and functional status on their treatment recommendations. Results: The proportion of oncologists who recommended adjuvant chemotherapy decreased as the patient's age increased or as the patient's functional status and health status decreased. For 96% of physicians (95% CI, 82-100%), patient age influenced chemotherapy recommendations, controlling for health/functional status; the same proportion of respondents were influenced by health/functional status, controlling for patient age. There was increased variability in treatment recommendations as the patient's age increased or functional status and health status decreased. Conclusion: Among these medical oncologists who primarily treat breast cancer adjuvant treatment recommendations vary based on patient age, health, and functional status. Future studies are needed to correlate age, health, and functional status with the risks and benefits of adjuvant therapy so that consensus guidelines can be formed. A more comprehensive baseline assessment of the older patient, such as can be derived from a comprehensive geriatric assessment may be useful in this regard. © 2006 Elsevier Ireland Ltd. All rights reserved. |
| Keywords: | clinical article; aged; aged, 80 and over; review; cancer adjuvant therapy; chemotherapy, adjuvant; physician's practice patterns; breast cancer; health survey; practice guideline; age factors; breast neoplasms; high risk patient; cancer hormone therapy; health status; medical oncology; tamoxifen; medical practice; physician; antineoplastic agents, hormonal; hormone; trastuzumab; anastrozole; anthracycline; decision making; elderly; functional status; health care surveys; geriatric assessment; geriatrics; neoplasms, hormone-dependent; older patient; treatment decisions |
| Journal Title: | Critical Reviews in Oncology/Hematology |
| Volume: | 61 |
| Issue: | 3 |
| ISSN: | 1040-8428 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2007-03-01 |
| Start Page: | 255 |
| End Page: | 260 |
| Language: | English |
| DOI: | 10.1016/j.critrevonc.2006.09.002 |
| PUBMED: | 17098441 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 11" - "Export Date: 17 November 2011" - "CODEN: CCRHE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work